Clin2
NCT07734792Possibly a fitNot yet recruiting

Tirzepatide for stroke patients after clot removal

Acute Ischemic Stroke (AIS)

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests if tirzepatide, a diabetes drug, can improve recovery in people who had a stroke from a blocked large artery in the brain and then had the clot removed. It may help by reducing inflammation and improving blood sugar control.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
430 people
Ages
19 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old
  • You had a stroke caused by a blockage in a major artery in the front of the brain (carotid or middle cerebral artery), confirmed by imaging
  • Your stroke severity score (NIHSS) is between 6 and 25 before treatment
  • Brain imaging shows a certain amount of salvageable tissue (ASPECTS 6-10)
  • You are able to have the clot removal procedure within 24 hours of symptoms starting
  • You had no major disability before the stroke (mRS 0-1)
  • You have not received clot-dissolving medication (IV thrombolysis) for this stroke
  • You do not have active bleeding, severe kidney or liver disease, or low blood counts
  • You have not used GLP-1 or GIP receptor agonists before (like Ozempic, Mounjaro)
  • You do not have a personal or family history of medullary thyroid cancer or certain genetic conditions

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05728333Recruiting· Phase 2/Phase 3
Tirofiban or alteplase before clot removal in stroke

This trial tests whether giving either tirofiban or alteplase through a vein before a mechanical clot-removal procedure works better for an acute ischemic stroke. It may help improve how well blood flow returns and how much recovery patients can have after treatment.

Hangzhou, Zhejiang
NCT06373042Not yet recruiting· Phase 2/Phase 3
Tirofiban after successful stroke clot removal

This trial tests if adding a blood thinner called tirofiban after successful clot removal can improve recovery in people with severe stroke. It is for patients who had a large blockage and are treated within 24 hours of symptoms starting.

NCT07111806Not yet recruiting· Phase 3
Tirofiban after delayed clot-dissolving treatment for stroke

This trial tests if a medication called tirofiban can help people who had a stroke 4.5 to 24 hours ago and received clot-dissolving treatment (IVT). If you have had a stroke and your symptoms did not improve or got worse after IVT, this study might offer a way to prevent further disability.

Guangzhou, Guangdong
NCT07335107Not yet recruiting· Phase 3
Study of tirofiban after bridging therapy for stroke with artery blockage

This trial tests if a drug called tirofiban, given after clot removal and clot-busting medicine, can help people with a specific type of stroke caused by a hardened artery. It aims to see if it improves recovery and prevents new clots.

Beijing, Beijing Municipality
NCT06045156Recruiting
Tirofiban after clot-busting for stroke

This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.

Changchun, Jilin
NCT07727395Recruiting· Phase 3
Clot-busting drug after successful clot removal for stroke

This trial tests whether giving a clot-busting drug (alteplase) directly into the brain artery after a successful clot removal improves recovery in people with severe stroke. It is for patients who have had a thrombectomy and still have a large blocked artery in the front of the brain.

An Giang

Hear when a new Acute Ischemic Stroke (AIS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.